Ethnic Differences in PK and PD of Anti-Rheumatic Drugs
|
|
- Reynold Stone
- 5 years ago
- Views:
Transcription
1 2010 China-Japan Symposium on Global Clinical Trials and Ethnic Factors May 28 th, 2010, JW Marriott Hotel Beijing Ethnic Differences in PK and PD of Anti-Rheumatic Drugs Shinichi Kawai, MD, PhD Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
2 S. Kawai
3 (Kawai S. J Orthop Sci. 2003;8:259)
4 Immunosuppressive Drugs
5 Immunosuppressive Drugs for RA Anti-Metabolites Methotrexate, Azathioprine Calcineurin Inhibitors Cyclosporine, Tacrolimus T Cell T Cell APC Proliferation Function Pro-inflammatory Cytokines Inflammation & Immune Responses S. Kawai
6 H2N N OH N N N CH2 H N Folic acid CO H N COOH CH CH2 CH2 COOH H2N N NH2 N CH3 N CH2 N CO N Methotrexate H N COOH CH CH2 CH2 COOH
7 S. Kawai 1 st Visit 1 Year After
8 Interstitial Pneumonitis Complicated with MTX Therapy in RA Patient
9 (Modified from Kawai S. Nikkei Medical, Oct 2008)
10 RA 329 (F 265) MTX 144 (43.8%) >8mg/w 37 (24.7%) n MTX Doses (mg/w)
11 Relationship between Ages and MTX Doses of RA Patients in Our Clinic MTX Dose (mg/w) Age
12 Calcineurin Inhibitors
13 Tacrolimus and Cyclosporine Molecular formula C 44 H 69 NO 12 H 2 O C 62 H 111 N 11 O Macrolide 12 Molecular weigh Cyclic Polypeptide (Kitahara K & Kawai S. Curr Opin Rheumatol. 2007;19:238)
14 Mechanism of Action of Tacrolimus in T Cell T Cell PLC CD3 IP3 Ca Ag TCR IP3 Ca CD4 PLC Tacrolimus CaM CaM DAG P P CaN CaN FKBP DAG Activation of PKC NFAT Jun AP-1 NFAT CaN Fos AP-1 Jun Fos Activation of PKC Production of Cytokines
15 Human Tacrolimus-Binding Proteins FKBP a Refseq ID Locuslink b Class Chromosome FKBP12 FKBP C 20p13 FKBP12.6 FKBP1B 2281 C 2p23 FKBP25 FKBP N 14q21 FKBP135 KIAA N 9q32 FKBP36 FKBP TPR 7q11 FKBP37 AIP 9049 TPR 11q13 FKBP38 FKBP TPR 19p12 FKBP51 FKBP TPR 6p21 FKBP52 FKBP TPR 12p13 FKBP13 FKBP ER 11q13 FKBP19 FKBP ER 12q13 FKBP22 FKBP ER 7p15 FKBP23 FKBP ER 2q31 FKBP60 FKBP ER 7p11 FKBP65 FKBP ER 17q21 C = cytoplasmic, N = nuclear, TPR = TPR-containing, ER = secretory pathway. a FKBPs are grouped by subfamily (see Results section). b Locuslink IDs and chromosomal positions as recorded in the NCBI Locuslink database are shown. (Rulten SL, et al. Mamm Genome 2006;17:322)
16 Cyclophilins kda Distribution CypA 18 cytoplasm CypB 22 secretory pathways CypC 23 secretory pathways CypD 22 mitochondria CypE ND nuclear Cyp40 40 cytoplasm CypNK ND cytoplasm ND; not determined (Kitahara K & Kawai S. Curr Opin Rheumatol 2007;19:238)
17 Cyclosporine
18 Year Author Study design Period Dose No. of patients Results Ref Hetland et al. R, DB, PC 52wk (1) MTX 7.5mg/wk + CyA 2.5mg/kg/day + i.a. Betamethasone 160 CyA+MTX > MTX 50 (2) MTX 7.5mg/wk + i.a. Betamethasone 2006 Karanikolas et al. O, R, P 12mo (1) CyA 2.5-5mg/kg/day (2) LEF 20mg/day (3) (1) + (2) 106 CyA+LEF > CyA or LEF Sarzi-Puttini et al. O, R 12mo (1) CyA 3-5mg/kg/day + MTX mg/wk (2) CyA 3-5mg/kg/day + HCQ 400mg/day (3) CyA 3-5mg/kg/day 105 CyA+MTX > CyA+HCQ Miranda et al. R, DB, PC 12mo (1) CyA 2.5-5mg/kg/day + Clq 150mg/day (2) CyA 2.5-5mg/kg/day 149 NS Gerards et al. R, DB, PC 48wk (1) CyA 2.5-5mg/kg/day + MTX mg/wk (2) CyA 2.5-5mg/kg/day 120 CyA+MTX > CyA Marchesoni et al. R, SB 12mo (1) CyA 3-4mg/kg/day + MTX 10-20mg/wk (2) MTX 10-20mg/wk 61 CyA+MTX > MTX van den Borne et al. R, DB, PC 24wk (1) Clq mg/day (2) Clq mg/day + CyA 1.25mg/kg/day (3) Clq mg/day + CyA2.5mg/kg/day 88 CyA+Clq > Clq Bendix et al. R, DB, PC 6mo (1) CyA2.5-5mg/kg/day + i.m. gold 20-40mg (2) i.m. gold 20-40mg 40 NS Tugwell et al. R, DB, PC 6mo (1) CyA 2.5-5mg/day + MTX maximal tolerated dose (2) MTX maximal tolerated dose 148 CyA + MTX > MTX 42 O; open trial, R; randomized, DB; double blind, SB; single blind, PC; placebocontrolled Clq ; chloroquine, CyA; cyclosporin A, HCQ; hydroxychloroquine, mpsl; methylprednisolone, MTX; methotrexate, SSZ; sulfasalazine NS; not significant (Kitahara K & Kawai S. Curr Opin Rheumatol 2007;19:238)
19 Tacrolimus
20 ACR20 & 50 Response Rates for Tacrolimus Therapy in American RA Patients % Patients Placebo 1 mg 3 mg 5 mg (Furst DE, et al. Arthritis Rheum 2002;46:2020)
21 ACR20, 50, 70 Response Rates for Tacrolimus Therapy in American RA Patients (Yocum DE, et al. Arthritis Rheum 2003;48:3328)
22 ACR20 & 50 Response Rates for Tacrolimus Therapy in Japanese RA Patients (4Mo) (%) 50 *** Placebo 1.5mg 3 mg ACR20 ACR50 (Kondo Y, et al. J Rheumatol 2004;31:243) *** p<0.001 (vs. placebo) # p<0.05 (vs.1.5mg/day)
23 Effects of Tacrolimus on RA Patients CRP mg/dl pre 4W 8W 12W 16W 1 ESR mm/hr pre 4W 8W 12W 16W Placebo 5 Placebo ** P<0.01 * *** *** 3mg/day 1.5mg/day ** *** P<0.001 *** 3mg/day * P<0.05 * 1.5mg/day *** *** (Kondo Y, et al. J Rheumatol 2004;31:243)
24 56y.o. Female Patient with RA 5mg/d Prednisolone 4mg/d 3mg/d MTX 10.5mg/w Tacrolimus 3mg/d 2mg/d Hb g/dl Folinate 40mg, 5d Admission Anemia ESR mm/h ESR Serum CRP mg/dl Serum CRP Kawai S & Akimoto K
25 ACR20, 50, and DAS28 Response Rates for Tacrolimus and Mizoribine in Japanese RA Patients (Kawai S, et al. J Rheumatol 2006;33:2153)
26 Open Study of Tacrolimus in the Elderly Japanese RA Patients 100 ACR20 ACR50 80 ( ): Patients Response Rate (%) % (27) 18.5% (10) 40.0% (10) 58.6% (17) 0 All (n=54) Insufficient to MTX (n=25) Insufficient to DMARD (n=29) [Kawai S & Yamamoto K. Rheumatology (Oxford) 2006;45:441]
27 Comparison of ACR Response Rates to Tacrolimus in RCT for RA Patients * * * * * * Not determined (Kitahara K & Kawai S. Curr Opin Rheumatol 2007;19:238)
28 % 34.4 % of Patients % 40% Stop Placebo 1 mg 3 mg 5 mg (Furst DE, et al. Arthritis Rheum 2002;46:2020)
29 Increase in Serum Cr after Tacrolimus & MTX Therapy in American RA Patients (Kremer JM, et al. Arthritis Rheum 2003;48:2763)
30 Cumulative Treatment Cotinuation Rate to Tacrolimus Therapy for RA Patients 100 Cumulative treatment continuation rate (%) Gastroenteropathies Other Reasons Adverse Reactions Total (n=42) Infections, Hyperglycemia, Hypertension, Renal Dysfunction, etc Administration period (days) (Akimoto K, et al. Clin Rheumatol, 2008;27:1393
31 Biological Agents
32 Recent Biological Agents Rituximab a-cd20mab Ocrelizumab a-cd20mab Abatacept (CTLA4-Ig) Proinflammatory Cytokines TNF, IL-1, IL-6 Neutrophils S. Kawai Infliximab Etanercept Adalimumab Tocilizumab Macrophages
33 TNF Adalimumab Etanercept Infliximab
34 Various Biologic Drugs: TNF Antagonists Compound Approved Chimeric anti-tnf mab (lgg1) TNF-receptor p75 lgg1 construct Fully human anti-tnf mab (IgG1) In late-stage development PEGylated humanized anti-tnf Fab fragment TNF-receptor p55 PEG Infliximab Etanercept Adalimumab CDP870 PEG-sTNF-R1 Human Mouse Synthetic element = Polyethylene glycol
35 Infliximab
36 Concentration versus Time Curves for Infliximab in Our RA Patients (Nishio S, et al. Mod Rheumatol 2009;19:329)
37 PK Data for Our RA Patients and A Japanese Clinical Trial C1h (µg/ml) Ctrough (µg/ml) t 1/2 (hrs) Patient 1 (1.5 mg/kg) Patient 2 (1 mg/kg) Trial median* (Interquartile range) ( ) (< ) ( ) (Nishio S, et al. Mod Rheumatol 2009;19:329)
38 Fcg Receptor Gene Polymorphisms in Our RA Patients Controlled by Low-Dose Infliximab Patient 1 Patient 2 FcγRIIA 131H/H 131H/H FcγRIIIA 176F/F 176F/F FcγRIIIB NA1/NA2 NA2/NA2 (Nishio S, et al. Mod Rheumatol 2009;19:329)
39 5 Cumulative Incidence Rate (%) Male Aged Advanced RA Pulmonary Diseases Bacterial Pneumonia Interstitial Pneumonia Pneumocyctis pneumonia Tuberculosis Days since Start of Administration of Infliximab (Takeuchi T, et al. Ann Rheum Dis 2008;67:189)
40 Comparisons between PMS of Infliximab and Etanercept in Japanese RA Patients Infliximab Etanercept Duration Patient Number 5,000 7,091 Adverse Event 1,401 (28.0%) 2,173 (30.6%) Severe A.E. 308 (6.2%) 403 (5.7%) Pneumonia 108 (2.2%) 102 (1.4%) Tuberculosis 14 (0.28%) 10 (0.14%) PCP 25 (0.50%) 16 (0.23%) Int. Pneumonia 22 (0.44%) 44 (0.62%) PCP= Pneumocystis Pneumonia (Takeuchi T, et al. Ann Rheum Dis 2008;67:189) (Koike T, et al. J Rheumatol. 2009;36:898)
41 (Risk Factors: Elderly; >6mg Prednisolone; Pulmonary Diseases) 100 Cumulative Probability of Pneumocystis Pneumonia (%) With 3 risk factors (n=7) With 2 risk factors (n=13) With 1 risk factors (n=49) With 0 risk factors (n=54) Weeks (Harigai M, et al. N Engl J Med 2007; 357:1874)
42 Etanercept
43 Structure of Etanercept
44 Serum Etanercept in Japanese Volunteers (Kawai S, et al. J Clin Pharmacol 2006;46:418)
45 Comparison of PK of Etanercept between Japanese & American Volunteers (Kawai S, et al. J Clin Pharmacol 2006;46:418)
46 Relationship between AUC 0- and Dose of Etanercept in Japanese & American Healthy Subjects 500 AUCinf (mg hr/l) y = x R 2 = US ( & ) JP (0881A1) DOSE (mg) (Calculated from Kawai S, et al. J Clin Pharmacol 2006;46:418)
47 Simulation of Serum Etanercept Concentration Serum Concentration Concentration of Etanercept (ng/ml) mg sc t max 47 h C max ng/ml t 1/2 80 h Time Time (week) (weeks) (Calculated from Kawai S, et al. J Clin Pharmacol 2006;46:418)
48 Comparison of PD of Etanercept between Japanese & American Patients Improvement / /50 32/ /79 Placebo ETA 10mg 2 times/w ETA 25mg 2 times/w / /77 0 p vs Placebo Fisher p 0.01 vs Placebo χ 2 test) p vs Placebo χ 2 test)
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationMonoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationFurther cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients
Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients Pelham Barton, West Midlands Health Technology Assessment Collaboration (WMHTAC) This document relates
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationBRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1
BRIEFING DOCUMENT Application Type BLA Submission Number 125118/0 Reviewer Name Team Leader Division Director Established Name (Proposed) Trade Name Applicant Formulation Dosing Regimen Indication Intended
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAdult-onset Still s disease a polygenic autoinflammatory disease
Adult-onset Still s disease a polygenic autoinflammatory disease Tom Pettersson, MD, PhD University of Helsinki and Helsinki University Central Hospital IL-1 mediated diseases past present and future Såstaholm
More informationAlthough this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as
Although this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. Forward-Looking
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationBenefit/risk of combination therapies
Benefit/risk of combination therapies D. Zerkak, M. Dougados Rheumatology B Department, Cochin Hospital, René Descartes University, Paris, France. Djamila Zerkak, MD; Maxime Dougados, MD. Please address
More informationISSN: (Print) (Online) Journal homepage:
mabs ISSN: 1942-0862 (Print) 1942-0870 (Online) Journal homepage: https://www.tandfonline.com/loi/kmab20 Certolizumab Pegol Niti Goel & Sue Stephens To cite this article: Niti Goel & Sue Stephens (2010)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationWhat I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationEvaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice
Evaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice Provided by Integrity Continuing Education, Inc. Supported by an educational
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationNovel anti-inflammatory compounds for ulcerative colitis and rheumatoid arthritis therapy
Novel anti-inflammatory compounds for ulcerative colitis and rheumatoid arthritis therapy JANSA, P. 1, HOLÝ, A. 1, ZÍDEK, Z. 2, JANEBA, Z. 1, KOLMAN, V. 1 1 Institute of Organic Chemistry and Biochemistry
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationBasic Approach/Goals. Medical Management of Rheumatic Diseases. Acetaminophen. Anti-inflammatories (NSAIDs) Steroids.
Basic Approach/Goals Medical Management of Rheumatic Diseases Diane Lacaille, Rheumatologist ACE Workshop April 23, 2018 1) Symptom control: Acetaminophen, NSAIDs, steroids (intraart, po) 2) Prevention
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationRheumatoid Arthritis. Module III
Rheumatoid Arthritis Module III Management: Biological disease modifying anti-rheumatic drugs, glucocorticoids and special situations (pregnancy & lactation) Dr Ved Chaturvedi MD, DM Senior Consultant
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationClinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:
Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity
Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Daniel E Furst MD University of California in Los Angeles University of Washington University of Florence
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationClinical Policy: Baricitinib (Olumiant) Reference Number: CP.PHAR.135 Effective Date: Last Review Date: 11.18
Clinical Policy: (Olumiant) Reference Number: CP.PHAR.135 Effective Date: 07.24.18 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationUNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationBiologic therapy for Rheumatoid arthritis. Paul Etau Ekwom Physician and Rheumatologist
Biologic therapy for Rheumatoid arthritis Paul Etau Ekwom Physician and Rheumatologist Objectives Case presentation of patient with rheumatoid arthritis on a biologic therapy. Discuss biologic therapy
More informationFigure 1. Study flow diagram. Reasons for withdrawal during the extension phase are included in the flow diagram. 508 patients enrolled and randomized
508 patients enrolled and randomized 126 assigned to sequential monotherapy (group 1) 121 assigned to step-up combination therapy (group 2) 133 assigned to initial combination therapy with prednisone (group
More informationTNF-α antagonists improve arterial stiffness in patients with rheumatoid arthritis: a meta-analysis
TNF-α antagonists improve arterial stiffness in patients with rheumatoid arthritis: a meta-analysis G.Georgiopoulos 1, D.Terentes-Printzios 1, C.Vlachopoulos 1, A.Gravos 1, P.Pietri 1, C.Georgakopoulos
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More informationMeta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis
Jansen et al. BMC Musculoskeletal Disorders (2016) 17:348 DOI 10.1186/s12891-016-1195-4 RESEARCH ARTICLE Open Access Meta-analysis of long-term joint structural deterioration in minimally treated patients
More informationJAK Inhibitors and Safety
JAK Inhibitors and Safety Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health, and Preventive Medicine Oregon Health & Science University Learning Objectives
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationXeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationRecommendations for RA management: what has changed?
The 2016 Update of the EULAR Recommendations for RA management: what has changed? Baltics Rheumatology Conference Vilnius, September 21-22 Prof. Diego Kyburz University Hospital of Basel Switzerland Multiple
More informationReview. Margaret Har Yin Ma 1, Andrew P Cope 2 & David L Scott 1,2
Review Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate We evaluated the frequency and type of adverse
More informationACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationClinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis
For reprint orders, please contact reprints@expert-reviews.com Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis Expert Rev. Clin. Pharmacol. 6(2), 123 137
More informationTHERAPY in RHEUMATOLOGY
THERAPY in RHEUMATOLOGY RA OA AS Systemic diseases SLE Dermatomyositis Scleroderma Gout Rheumatic fever Lyme disease RHEUMATOID ARTRHRITIS Education Build a cooperative long-term relationship Use materials
More informationDrug selection in Rheumatoid Arthritis
Drug selection in Rheumatoid Arthritis PROFESSOR KHAN ABUL KALAM AZAD PROFESSOR, DEPARTMENT OF MEDICINE DHAKA MEDICAL COLLEGE Rheumatoid arthritis Autoimmune disease Onset generally occurs between 30 and
More informationAmerican College of Rheumatology Analyst and Investor Meeting November 6, 2011
American College of Rheumatology 2011 Analyst and Investor Meeting November 6, 2011 Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements Our discussions during this meeting
More informationThe Journal of Rheumatology Volume 41, no. 1
The Journal of Volume 41, no. 1 Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan Takao Koike, Masayoshi Harigai, Shigeko Inokuma,
More informationRheumatoid arthritis (RA) has no known PROCEEDINGS THERAPEUTIC PRINCIPLES AND GOALS * Elizabeth Grace, RN ABSTRACT
THERAPEUTIC PRINCIPLES AND GOALS * Elizabeth Grace, RN ABSTRACT Permanent joint damage occurs early in rheumatoid arthritis (RA) pathogenesis, thus early aggressive treatment is recommended. Treatment
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationCombination therapy in. rheumatoid arthritis
Chapter 2 Combination therapy in rheumatoid arthritis YPM Goekoop CF Allaart FC Breedveld BAC Dijkmans Curr Opin Rheumatol 2001;13:177-83. ABSTRACT It has become clear that early suppression of rheumatoid
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationThe BeSt way of withdrawing biologic agents
The BeSt way of withdrawing biologic agents C.F. Allaart 1, W.F. Lems 2, T.W.J. Huizinga 1 1 Department of Rheumatology, Leiden University Medical Center, Leiden; 2 Department of Rheumatology, Free University
More informationN Nishimoto, 1 N Miyasaka, 2 K Yamamoto, 3 S Kawai, 4 T Takeuchi, 5 J Azuma 1. Extended report
1 Osaka University, Osaka, Japan; 2 Tokyo Medical and Dental University, Tokyo, Japan; 3 University of Tokyo, Tokyo, Japan; 4 Toho University Omori Medical Center, Tokyo, Japan; 5 Saitama Medical Center/
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationinfliximab, 100mg, powder for concentrate for solution for infusion (Inflectra ) SMC No. (1007/14) Hospira UK Ltd.
infliximab, 100mg, powder for concentrate for solution for infusion (Inflectra ) SMC No. (1007/14) Hospira UK Ltd. 07 November 2014 (Issued 06 March 2015) The Scottish Medicines Consortium (SMC) has completed
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationDMARD s in Clinical Practice
DMARD s in Clinical Practice Professor Md. Mahabubul Islam Majumder Professor & Head, Department of Medicine Comilla Medical College, Comilla Bangladesh Disease-modifying antirheumatic drugs (DMARDs) A
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:
Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:
Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 1.1.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More information